ReviewJournal of clinical medicine2018
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Review in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer.Therapeutic advances in medical oncology · 2025Article
- Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.Journal of the Egyptian National Cancer Institute · 2024Article
- Biomarker testing in lung cancer: from bench to bedside.Oncology reviews · 2024Review
- Droplet Digital PCR as a Molecular Tool for the Detection of theBalkan journal of medical genetics : BJMG · 2023Article
- Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer.Frontiers in oncology · 2023Review
- Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring anJCO precision oncology · 2022Article
- Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.Healthcare (Basel, Switzerland) · 2022Article
- Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia.JTO clinical and research reports · 2022Article
- Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.PloS one · 2022Article
- The Interaction of the IFNJournal of oncology · 2022Article
- Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.Investigational new drugs · 2021Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- Comparison ofOncotarget · 2021Article
- Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples.Diagnostic pathology · 2021Article
- Review
- Comprehensive tumor molecular profile analysis in clinical practice.BMC medical genomics · 2021Article
- Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.BMC cancer · 2021Observational
- The Outer Retinal Membrane Protein 1 Could Inhibit Lung Cancer Progression as a Tumor Suppressor.Computational and mathematical methods in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent changes in lung cancer care, including new approvals in first line and the introduction of high-throughput molecular technologies in routine testing led us to question ourselves on how deeper molecular testing may be helpful for the optimal use of targeted drugs. In this article, we review recent results in the scope of personalized medicine in lung cancer. We discuss biomarkers that have a therapeutic predictive value in lung cancer with a focus on recent changes and on the clinical value of large scale sequencing strategies. We review the use of second- and third-generation EGFR and ALK inhibitors with a focus on secondary resistance alterations. We discuss anti-BRAF and anti-MEK combo, emerging biomarkers as NRG1 and NTRKs fusions and immunotherapy. Finally, we discuss the different technical issues of comprehensive molecular profiling and show how large screenings might refine the prediction value of individual markers. Based on a review of recent publications (2012⁻2018), we address promising approaches for the treatment of patients with lung cancers and the technical challenges associated with the identification of new predictive markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.